Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FZQ10
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,424
Award facts
- Contract value 100% obligated
- $3,424.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for Xolair 300 mg/2 mL auto-injector vials valued at $3,424.46. The award, issued on September 3, 2025, with a completion date of September 24, 2025, represents a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group, based in Park Ridge, Illinois, will perform the delivery at its location. This delivery order falls under the company's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.99 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military healthcare facilities.
As a critical supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group has established itself as a reliable distributor of prescription medications, biologics, and medical consumables to Department of Defense healthcare sites. The Xolair delivery represents one of numerous pharmaceutical items the company supplies through its IDC arrangement, which encompasses branded and generic drugs, vaccines, specialty medications, and auto-injectors supporting medical supply needs across military health facilities nationwide. The firm fixed-price structure ensures predictable costs for this specialized immunological treatment delivery to federal healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FZQ10?
SPE2DB25FZQ10 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 3, 2025.
How much is contract SPE2DB25FZQ10 worth?
The government has obligated $3,424 on SPE2DB25FZQ10.
Is contract SPE2DB25FZQ10 an order under another contract?
Yes. SPE2DB25FZQ10 is a delivery order under SPE2DB22D9102, an indefinite delivery contract.
Was contract SPE2DB25FZQ10 competed?
The extent of competition for SPE2DB25FZQ10 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award